These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 29269135

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression.
    Kaur P, Thiruchelvan M, Lee RC, Chen H, Chen KC, Ng ML, Chu JJ.
    Antimicrob Agents Chemother; 2013 Jan; 57(1):155-67. PubMed ID: 23275491
    [Abstract] [Full Text] [Related]

  • 25. Bis(benzofuran-thiazolidinone)s and bis(benzofuran-thiazinanone)s as inhibiting agents for chikungunya virus.
    Hwu JR, Gupta NK, Tsay SC, Huang WC, Albulescu IC, Kovacikova K, van Hemert MJ.
    Antiviral Res; 2017 Oct; 146():96-101. PubMed ID: 28830714
    [Abstract] [Full Text] [Related]

  • 26. Recombinant Baculovirus: A Flexible Drug Screening Platform for Chikungunya Virus.
    Varikkodan MM, Chen CC, Wu TY.
    Int J Mol Sci; 2021 Jul 23; 22(15):. PubMed ID: 34360656
    [Abstract] [Full Text] [Related]

  • 27. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV Agents.
    Jadav SS, Sinha BN, Hilgenfeld R, Jayaprakash V.
    Curr Comput Aided Drug Des; 2017 Nov 10; 13(4):346-361. PubMed ID: 28294048
    [Abstract] [Full Text] [Related]

  • 28. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
    Delang L, Segura Guerrero N, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P.
    J Antimicrob Chemother; 2014 Oct 10; 69(10):2770-84. PubMed ID: 24951535
    [Abstract] [Full Text] [Related]

  • 29. Imidazonaphthyridine effects on Chikungunya virus replication: Antiviral activity by dependent and independent of interferon type 1 pathways.
    Ruiz UEA, Santos IA, Grosche VR, Fernandes RS, de Godoy AS, Torres JDA, Freire MCLC, Mesquita NCMR, Guevara-Vega M, Nicolau-Junior N, Sabino-Silva R, Mineo TWP, Oliva G, Jardim ACG.
    Virus Res; 2023 Jan 15; 324():199029. PubMed ID: 36565816
    [Abstract] [Full Text] [Related]

  • 30. Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
    Ching KC, Kam YW, Merits A, Ng LF, Chai CL.
    J Med Chem; 2015 Dec 10; 58(23):9196-213. PubMed ID: 26540338
    [Abstract] [Full Text] [Related]

  • 31. Exploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus.
    Martins DOS, Ruiz UEA, Santos IA, Oliveira IS, Guevara-Vega M, de Paiva REF, Abbehausen C, Sabino-Silva R, Corbi PP, Jardim ACG.
    Pharmacol Rep; 2024 Oct 10; 76(5):1147-1159. PubMed ID: 39150661
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection.
    Abdelnabi R, Jochmans D, Verbeken E, Neyts J, Delang L.
    Antiviral Res; 2018 Jan 10; 149():113-117. PubMed ID: 28958920
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Protein kinases C as potential host targets for the inhibition of chikungunya virus replication.
    Abdelnabi R, Amrun SN, Ng LF, Leyssen P, Neyts J, Delang L.
    Antiviral Res; 2017 Mar 10; 139():79-87. PubMed ID: 28039020
    [Abstract] [Full Text] [Related]

  • 36. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms.
    Ho YJ, Liu FC, Yeh CT, Yang CM, Lin CC, Lin TY, Hsieh PS, Hu MK, Gong Z, Lu JW.
    Antiviral Res; 2018 Nov 10; 159():134-142. PubMed ID: 30300716
    [Abstract] [Full Text] [Related]

  • 37. In silico and in vitro evaluation of silibinin: a promising anti-Chikungunya agent.
    Dutta SK, Sengupta S, Tripathi A.
    In Vitro Cell Dev Biol Anim; 2022 Mar 10; 58(3):255-267. PubMed ID: 35381943
    [Abstract] [Full Text] [Related]

  • 38. Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection.
    Ashbrook AW, Lentscher AJ, Zamora PF, Silva LA, May NA, Bauer JA, Morrison TE, Dermody TS.
    mBio; 2016 May 24; 7(3):. PubMed ID: 27222471
    [Abstract] [Full Text] [Related]

  • 39. Stress granule components G3BP1 and G3BP2 play a proviral role early in Chikungunya virus replication.
    Scholte FE, Tas A, Albulescu IC, Žusinaite E, Merits A, Snijder EJ, van Hemert MJ.
    J Virol; 2015 Apr 24; 89(8):4457-69. PubMed ID: 25653451
    [Abstract] [Full Text] [Related]

  • 40. In vitro and in vivo studies reveal α-Mangostin, a xanthonoid from Garcinia mangostana, as a promising natural antiviral compound against chikungunya virus.
    Patil P, Agrawal M, Almelkar S, Jeengar MK, More A, Alagarasu K, Kumar NV, Mainkar PS, Parashar D, Cherian S.
    Virol J; 2021 Feb 28; 18(1):47. PubMed ID: 33639977
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.